Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer-Reference-Cited by-同舟云学术

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Published:2023-08-24 Issue:1 Volume:24 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Park Yoon Sun¹²,kim Joseph¹²,Ryu Yea Seong¹,moon Jai-Hee¹,shin Yu Jin¹,kim Jeong Hee¹,hong Seung-Woo¹,jung Soo-A¹,lee Seul¹,kim Seung-Mi¹,lee Dae Hee¹,kim Do Yeon¹²,yun Hyeseon¹²,you Ji-Eun¹²,yoon Dong Il¹²,kim Chul Hee¹²,koh Dong-In¹,jin Dong-Hoon³⁴^ORCID

Affiliation:

1. Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea

2. Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

3. Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Republic of Korea

4. Department of Convergence Medicine, Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea

Funder

no funding

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2023.2246208

Reference59 articles.

1. Comprehensive review of targeted therapy for colorectal cancer

2. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

4. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

5. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defensins: Exploring Their Opposing Roles in Colorectal Cancer Progression;Cancers;2024-07-23